Answers are grounded in this paper and cite their sources.
Circulating biomarkers nucleic acids, proteins, and metabolites have been used in several adult oncologic processes to affect early detection, measure response to treatment, and offer prognostic information. The identification and validation of biomarkers for pediatric brain tumors, however, has been meager by comparison. Early detection and serial screening of pediatric brain tumors has the potential to improve outcomes by allowing for rapid therapeutic interventions and more targeted therapies. This is particular resonant for pediatric brain tumors where treatment success is heavily dependent on early surgical intervention. This highlights the need for biomarker development in pediatric neuro-oncology. The authors reviewed current circulating biomarker targets in various biofluid reservoirs and discuss the current barriers to biomarker development in pediatric neuro-oncology patients.
No takes yet. Share an insight, caveat, or question.
Bookland et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: